TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use
The TGA approved Foundayo, a GLP-1 weight loss pill by Lilly Australia, for use in Australia. The drug, similar to Ozempic and Wegovy, aids weight loss and treats type 2 diabetes. Lilly Australia reported successful clinical trials with over 10,000 patients. Foundayo is now available via private prescription but not yet on the Pharmaceutical Benefits Scheme.
How this was made

The 30-second read
Why it matters
This is a direct regulatory catalyst for Lilly’s Australian GLP-1 product, with near-term availability via private prescription but potential demand constraints until PBS reimbursement and with safety/interaction considerations.
Market read
Regulatory approval for an oral GLP-1 can re-rate category growth expectations, but the lack of PBS inclusion and limited commercial specifics keep the immediate trading impact moderate.
What to watch
Key missing details for trading include efficacy vs injectables, pricing, formulary/PBS timeline, and real-world tolerability during dose escalation, all of which can materially affect uptake despite regulatory clearance.
Background
The Therapeutic Goods Administration (TGA) cleared Foundayo, described as an Ozempic-style daily GLP-1 pill (small-molecule) for weight loss and type 2 diabetes in Australia.
Ticker impact
Lilly’s Australian unit says TGA cleared its GLP-1 pill Foundayo for weight loss and type 2 diabetes, with availability expected within days.
Shares may face upward pressure as the market prices in expanded GLP-1 franchise reach via an oral option, tempered by reimbursement and competitive dynamics.
The article is a first-time TGA clearance for Lilly’s product, which is a direct catalyst. However, it does not provide commercial scale, pricing, or trial efficacy details, and notes PBS listing is still pending.
Market effects
Adds competitive pressure within the GLP-1 space by validating an oral small-molecule format, potentially shifting expectations for future oral GLP-1 launches and payer adoption timelines.
Could accelerate GLP-1 access in Australia via private prescriptions immediately, while PBS non-inclusion may delay broader volume until reimbursement decisions.
Supports the broader global narrative that oral GLP-1s are moving from trials to regulators, which can influence sentiment across large pharma and oral GLP-1 developers.
Counterpoint
The approval may not translate into meaningful near-term revenue because Foundayo is not yet on Australia’s Pharmaceutical Benefits Scheme and the article emphasizes side-effect and drug-interaction warnings.
Key entities
- drugFoundayo
Daily oral GLP-1 pill cleared by Australia’s TGA for weight loss and type 2 diabetes; expected availability within days.
- regulatorTherapeutic Goods Administration (TGA)
Australian regulator that approved Foundayo for use.
- companyLilly (Australia)
Said Foundayo is a first-of-its-kind GLP-1 pill and highlighted trial scale and access plans.



